IL17A and chronic obstructive pulmonary disease: Similarly, an increase in the RORγ expression was also seen in COPD patients along with an increase in the IL-17+ cell-related chemokine receptors CCR6 and IL-23R in at least 10–20% of patients28, providing further evidence for a potential significant role of RORγ as a therapeutic target in COPD.